Brineura
cerliponase alfa · KIT · BioMarin Pharmaceutical Inc.
Brineura (cerliponase alfa) is an enzyme replacement therapy administered as directed by your healthcare provider to treat CLN2 disease, a rare inherited disorder affecting the nervous system. This medication works by replacing a deficient enzyme to help slow the progression of neurological symptoms in patients with this condition.
Key Facts
- Brand Name
- Brineura
- Generic Name
- cerliponase alfa
- NDC Code (Product)
68135-811- Manufacturer
- BioMarin Pharmaceutical Inc.
- Dosage Form
- KIT
- Marketing Status
- Application #
- BLA761052
- Marketing Start
- 04/27/2017
Recall History
No Recall HistoryFrequently Asked Questions
What is Brineura used for?
Brineura (cerliponase alfa) is an enzyme replacement therapy administered as directed by your healthcare provider to treat CLN2 disease, a rare inherited disorder affecting the nervous system. This medication works by replacing a deficient enzyme to help slow the progression of neurological symptoms in patients with this condition.
Is Brineura a controlled substance?
Brineura is not classified as a controlled substance by the DEA.
What is the generic name for Brineura?
The generic name for Brineura is cerliponase alfa. There are no other listed brand versions of cerliponase alfa.
What is the NDC code for Brineura ?
The NDC (National Drug Code) for Brineura is 68135-811, listed by BioMarin Pharmaceutical Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)